Compare · IBRX vs MRNA
IBRX vs MRNA
Side-by-side comparison of ImmunityBio Inc. (IBRX) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IBRX and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $24.53B, about 3.0x IBRX ($8.04B).
- Over the past year, IBRX is up 179.4% and MRNA is up 97.7% - IBRX leads by 81.7 points.
- MRNA has been more active in the news (11 items in the past 4 weeks vs 4 for IBRX).
- MRNA has more recent analyst coverage (25 ratings vs 6 for IBRX).
- Company
- ImmunityBio Inc.
- Moderna Inc.
- Price
- $7.66+2.75%
- $61.80-2.14%
- Market cap
- $8.04B
- $24.53B
- 1M return
- +13.74%
- +11.57%
- 1Y return
- +179.38%
- +97.70%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2018
- News (4w)
- 4
- 11
- Recent ratings
- 6
- 25
ImmunityBio Inc.
ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer vaccine to deliver tumor-associated antigens and neoepitopes; and a human adenovirus 5 COVID-19 vaccine. The company was founded in 2014 and is based in San Diego, California.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest IBRX
- Director Cohen Cheryl sold $1,246,941 worth of shares (131,210 units at $9.50) as part of a pre-agreed trading plan and exercised 55,979 shares at a strike of $2.98, decreasing direct ownership by 37% to 125,386 units (SEC Form 4)
- Director Selecky Christobel sold $1,439,066 worth of shares (159,478 units at $9.02) as part of a pre-agreed trading plan and exercised 159,478 shares at a strike of $2.99 (SEC Form 4)
- Director Selecky Christobel exercised 96,722 shares at a strike of $2.94 and sold $871,216 worth of shares (96,722 units at $9.01) as part of a pre-agreed trading plan (SEC Form 4)
- Director Simon Barry J. sold $196,908 worth of shares (25,000 units at $7.88) as part of a pre-agreed trading plan, decreasing direct ownership by 0.88% to 2,802,788 units (SEC Form 4)
- SEC Form 4 filed by Director Blaszyk Michael D
- SEC Form 4 filed by Director Wendel Bruce
- SEC Form 4 filed by Director Maxwell Linda
- SEC Form 4 filed by Director Cohen Cheryl
- SEC Form 4 filed by Director Clark Wesley
- SEC Form 4 filed by Director Selecky Christobel
Latest MRNA
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester